Caraway’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. We believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multiple neurodegenerative diseases, many of which are associated with cognitive impairment. We aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases.
- Josh Resnick CEO
- Magdalene Moran President and CSO